Onkologie 2020: 14(Suppl.D): 89-91 | DOI: 10.36290/xon.2020.047
Immunotherapy for synchronous advanced lung cancer and urothelial carcinoma: initial experience
- Onkologické oddělení, Klaudiánova nemocnice, Mladá Boleslav
Immunotherapy is a method that has been known in oncology for decades. Specific immunotherapy has been used until present day (e.g. the BCG vaccine in treating bladder cancer). The previously used non-specific immunotherapy was effective particularly in renal adenocarcinoma and malignant melanoma (interferons, interleukin - 2). More recently, molecules that are targeted at immune checkpoints have been used. Treatment efficacy has increased and the spectrum of cancer diagnoses for which therapeutic efficacy was noted has expanded. These also include advanced non-small cell lung cancer. The case report describes such a case of synchronous double cancer of the lung and the urinary bladder.
Keywords: immunotherapy, pembrolizumab, non-small cell lung cancer, urothelial carcinoma.
Published: June 2, 2020 Show citation
References
- Tafuri A, et al. Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies; Clinical Genitourinary Cancer. Clin Genitourin Cancer. 2020; 31: S1558-7673(20)30013-6. doi: 10.1016/j.clgc.2020.01.004.
Go to original source... 
Go to PubMed... - Balar AV, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017; 18(11): 1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26. Go to original source... Go to PubMed...
- Fradet Y, et. Al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019; 30(6): 970-976. doi: 10.1093/annonc/mdz127. Go to original source... Go to PubMed...
- Reck M, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19): 1823-1833. Epub 2016 Oct 8. Go to original source... Go to PubMed...
- Úloha PD-1/PD-L1 signalizace v protinádorové imunitní odpovědi. Klin Onkol 2016; 29(Suppl. 4): 72-77. DOI: 10.14735/amko20164S72. Go to original source... Go to PubMed...